Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Other Operating Expenses (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Other Operating Expenses for 6 consecutive years, with $380000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Operating Expenses rose 113.18% to $380000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$4.1 million, a 13.51% decrease, with the full-year FY2024 number at $1.7 million, down 31.19% from a year prior.
  • Other Operating Expenses was $380000.0 for Q3 2025 at Vivos Therapeutics, up from -$5.2 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $2.3 million in Q4 2021 to a low of -$5.2 million in Q2 2025.
  • A 5-year average of $334822.1 and a median of $691000.0 in 2023 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: soared 339.03% in 2021, then plummeted 517.22% in 2024.
  • Vivos Therapeutics' Other Operating Expenses stood at $2.3 million in 2021, then crashed by 33.6% to $1.5 million in 2022, then plummeted by 63.71% to $553000.0 in 2023, then tumbled by 35.62% to $356000.0 in 2024, then rose by 6.74% to $380000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Other Operating Expenses are $380000.0 (Q3 2025), -$5.2 million (Q2 2025), and $335000.0 (Q1 2025).